Rise across the board! TOP10 brands in the 27 billion insulin market released

A few days ago, Ganli Pharmaceutical's first second-generation insulin was approved for listing, and its leading position has been consolidated. In recent years, the domestic market for insulin and its similar drugs has continued to rise. In 2020, the terminal sales of China's public medical institutions will be close to 27 billion yuan. The three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied a dominant position, while the three domestic pharmaceutical companies of Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up. The total market share of TOP10 brands exceeds 80%. Novo Nordisk has as many as 4 brands on the list. The sales of Ganli Pharmaceutical and United Laboratories on the list have grown strongly.

27 billion insulin market! Novo Nordisk, Sanofi and Eli Lilly are among the top three

Diabetes mellitus is a comprehensive metabolic disorder mainly caused by insulin secretion defects and/or its biological function obstacles, mainly with increased blood sugar. Clinically, hyperglycemia is the main feature, and typical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc., that is, "three more and one less" symptoms.

The number of diabetic patients in China currently ranks first in the world and is maintaining a growth trend. Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years. According to data from Menet.com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.91%.

Due to high technical barriers to insulin products, the three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market. Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up. The total market share of the three major foreign companies in 2020 will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.

It is worth mentioning that in recent years, Ganli Pharmaceutical's insulin product sales have continued to rise, and the market share has also continued to expand. In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.

TOP10 brands rose across the board! Gan Li, Tonghua Dongbao, and the Federation are on the list

Among the TOP10 brands of insulin and similar drugs, the sales of 10 brands have achieved varying degrees of growth, with a total market share of more than 80%. Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.

Sales of the two brands increased strongly. United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.46%.

There are 8 brands with sales of more than 1 billion yuan. Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.

6 major domestic new products are coming! Gan Li, Tonghua Dongbao, Dongyang Pharmaceutical...

Since 2019, although there are only a handful of insulin products approved for listing in the domestic market, they are quite bright.

In terms of imported products, Novo Nordisk's Degu aspart insulin injection (Novoga) and Sanofi's insulin glargine injection (Laiyoushi) were approved for import in 2019 and 2020, respectively. Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart). It is the world's first soluble dual insulin and fills the gap in the domestic market.

In terms of domestic products, a total of 6 insulin products have been approved for listing by local companies since 2019, including 4 companies including Dongyang Sun Pharmaceutical, Hefei Tianmai, Tonghua Dongbao, Ganli Pharmaceutical, and Ganli Pharmaceutical alone has won three products. Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.

In 2020, Ganli Pharmaceutical's insulin aspart injection and insulin aspart 30 injection were successively approved for marketing, both of which are third-generation insulins. On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product. This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin. Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.